Inclusie Gemetastaseerd of irresectabel melanoom met BRAF-mutatie in codon 600. Hoge tumorload waardoor immunotherapie niet mogelijk klachten niet benaderbaar door lokale therapie of progressie is op beschikbare lijnen…
Quality of life, cognitive function, and physical fitness of melanoma and NSCLC patients surviving more than 2 years after immune checkpoint inhibitor therapy Protocolnummer: 201800146 Eudract nummer: METc…
A multicenter, open label, phase III extension trial to study the long-term safety and efficacy in participants with advanced tumors who are currently on treatment or in follow-up…
Safe Stop Trial: observational study of the STOP & GO strategy of PD-1 blockade in advanced melanoma patients upon achieving a complete or partial response. EudraCT nummer: 2018-001384-23…
Inclusie Gemetastaseerd of irresectabel melanoom met BRAF-mutatie in codon 600. Klachten niet benaderbaar voor lokale therapie, progressief op beschikbare lijnen immunotherapie of contra-indicatie immunotherapie Keuze van BRAF-remmer is…
PD-L1 PET imaging in patients with an inoperable melanoma or NSCLC with brain metastasis and eligible for treatment with nivolumab. CA209-8UU imaging Protocolnummer: 2016255-322 EudraCT nummer: 2016-002308-22 METc…
Het aanwijzen van factoren die voorspellen welke patiënten baat hebben bij immunotherapie op basis van zeer persoonlijke tumorkenmerken. Protocolnummer: 1.0 April 2018 Eudractnummer: METc nummer: M17PTS (METc AVL)…
A Phase III randomized, 3-arm, open label, multicenter study of LGX818 plus MEK162 and LGX818 monotherapy compared with vemurafenib in patients with unresectable or metastatic BRAF V600 mutant…
A Phase II, Open-Label, Multicenter Study of Vemurafenib plus Cobimetinib (GDC-0973) in Unresectable Stage IIIc or Stage IV melanoma. (Response Monitoring and Resistance Prediction with Positron Emission Tomography…
Randomized phase III study comparing a non-myeloablative lymphocyte depleting regimen of chemotherapy followed by infusion of tumor infiltrating lymphocytes and interleukin-2 to standard ipilimumab treatment in metastatic melanoma…